Lilly
  • For Consumers
    • Getting Started
    • FAQ and Resources
  • House For Healthcare Providers
    • Bamlanivimab Antibody Playbook
    • Access
    • Dosage and Administration
    • Clinical Data
    • FAQ and Resources
Ask Lilly

We're here to help.

Phone Call:
Lilly COVID Hotline
(1-855-545-5921)
Link Visit Lilly Medical (HCP)
Question Submit a Question
Expand contact lilly
Skip to main content

Access

On this page, you’ll find information on how bamlanivimab is being distributed across the country and how to identify infusion sites of care in your state. Be sure to scroll down to our Access FAQs which also provide more information regarding the process to order product and reimbursement.

bamlanivimab vial box

The federal government, in conjunction with state health departments, will allocate supply of bamlanivimab to individual sites of care across the United States proportionally based on confirmed COVID-19 cases. Sites that have been allocated product will be contacted by and can agree to accept shipments from AmerisourceBergen, a distributor. If you are a healthcare provider and have questions about whether or not your site of care has been allocated product, you may contact your state health department directly. A list of state health departments can be found here. If you cannot get ahold of your state health department, or have additional questions, please call our dedicated Lilly COVID Hotline at 1-855-545-5921.

If you have a question about enrolling a patient in a clinical trial, please visit our Lilly Trial Guide.

Find an infusion site near you

Some states are partnering with the National Infusion Center Association (NICA) to make it easier to identify infusion site locations by state. Click "Go" to be redirected to the COVID infusion therapy search tool, hosted by NICA.* Please note that not all states are included and a site’s inclusion in this tool does not imply current availability of doses.

Go Right

*IMPORTANT INFORMATION: Infusion sites displayed in this tool have been authorized to administer antibody treatments for COVID-positive patients under Emergency Use Authorization. These antibody therapies are restricted to certain high-risk patients and require a drug order (similar to a prescription) from a Health Care Provider (HCP) for eligible patients. HCPs must verify eligibility of their patients and verify the availability of doses at an authorized infusion site before they refer an eligible patient to schedule an appointment to receive treatment at an authorized infusion site.

allocation flow chart allocation flow chart

Frequently Asked Questions

FAQs regarding access to bamlanivimab

The federal government, in conjunction with state health departments, will allocate supply of bamlanivimab to individual sites of care across the United States proportionally based on confirmed COVID-19 cases. Sites that have been allocated product will be contacted by and can agree to accept shipments from the distributor, AmerisourceBergen. If you are a healthcare provider and have questions about whether or not your site of care has been allocated product, you may contact your state health department directly. A list of state health department websites may be found: here. If you cannot get ahold of your state health department, or have additional questions, please call our dedicated Lilly COVID Hotline at 1-855-545-5921.

Through the federally-run allocation program, bamlanivimab will be purchased by the federal government and offered at no cost to states, sites of care, or patients. Services and ancillary expenses necessary to administer the infusion are the responsibility of the individual site of care and can be billed according to published Centers for Medicare & Medicaid Services (CMS) guidance found at www.cms.gov for Medicare patients. There you will find the specific code(s) for each COVID-19 monoclonal antibody product and specific administration code(s) for Medicare payment. The codes for bamlanivimab are included below for reference:

Q0239:

  • Long descriptor: Injection, bamlanivimab-xxxx, 700 mg
  • Short descriptor: bamlanivimab-xxxx

M0239:

  • Long Descriptor: intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring
  • Short Descriptor: bamlanivimab-xxxx infusion

Commercial reimbursement is anticipated but may be variable based on the individual plan.

If approved to receive bamlanivimab, a representative from AmerisourceBergen will reach out to you directly to let you know you have been approved to receive the allocated amount of product. When they reach out, they will provide you with information on how to receive product.
Bamlanivimab is authorized for use for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Ultimately, it is up to the federal and state governments to determine where allocated product will be offered. If you have questions about whether your site of care has been chosen or if you would like to request future allocation, please contact your state health department directly.
If you have been approved to receive allocation of product, AmerisourceBergen will reach out to you directly to confirm that you would like to receive the allocated amount of product. If you believe you have been approved to receive an allocation but have yet to be contacted please contact c19therapies@amerisourcebergen.com.
The federal government will allocate cases of bamlanivimab to states, territories, and identified agencies on a weekly basis. You can view the most updated allocation tables here.

Clinical investigators, hospitals or clinical sites interested in participating in one of Lilly’s clinical trials for a potential COVID-19 treatment should call 1-877-CT-LILLY (1-877-285-4559) or email covid19potentialsite@lilly.com

Genuine bamlanivimab

Ensuring the authenticity of bamlanivimab

Eli Lilly and Company is committed to patient safety and ensuring that people have accurate information about investigational bamlanivimab, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate bamlanivimab to protect patients from products that might be dangerous and lead to serious and life-threatening harm.

Checkmark
Bamlanivimab is authorized in the United States for use under an EUA and can only be accessed through the request of a treating physician.
Checkmark
Bamlanivimab is only administered intravenously.
Checkmark
Bamlanivimab is not taken orally and is not available in a capsule or tablet form.
Checkmark
Authentic bamlanivimab, manufactured by Eli Lilly and Company, will include the Lilly name and logo on the label, and is dispensed in a vial with either a salmon or slate cap.
Checkmark
Bamlanivimab is not sold online.
Checkmark
The authenticity of products acquired outside of the legitimate supply chain cannot be verified by Eli Lilly and Company.

If you believe you have purchased or have been offered counterfeit bamlanivimab, please report it to the FDA.

Bamlanivimab is authorized for use for treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

  • Bamlanivimab has not been approved, but has been authorized for emergency use by FDA.
  • Bamlanivimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the bamlanivimab under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Limitations of Authorized Use

  • Bamlanivimab is not authorized for use in patients:
    • who are hospitalized due to COVID-19, OR
    • who require oxygen therapy due to COVID-19, OR
    • who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.
  • Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes in hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.

Important Safety Information

There are limited clinical data available for bamlanivimab. Serious and unexpected adverse events may occur that have not been previously reported with bamlanivimab use.

Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions

There is a potential for serious hypersensitivity reaction, including anaphylaxis, with administration of bamlanivimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive therapy.

Infusion-related reactions have been observed with administration of bamlanivimab. Signs and symptoms of infusion related reactions may include:

  • fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, dizziness.

If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and/or supportive care.

Limitations of Benefit and Potential Risk in Patients with Severe COVID-19

Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. See Limitations of Authorized Use.

Adverse Events

Adverse events reported in at least 1% of BLAZE-1 clinical trial participants on bamlanivimab 700 mg and placebo were Nausea (3% vs 4%), Diarrhea (1% vs 5%), Dizziness (3% vs 2%), Headache (3% vs 2%), Pruritus (2% vs 1%) and Vomiting (1% vs 3%).

Use in Specific Populations

Pregnancy
There are insufficient data on the use of bamlanivimab during pregnancy. Bamlanivimab should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.

Breastfeeding
There are no available data on the presence of bamlanivimab in human or animal milk, the effects on the breastfed infant, or the effects on milk production. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

Health care providers should review the Fact Sheet for information on the authorized use of bamlanivimab and mandatory requirements of the EUA. Please see the FDA Letter of Authorization, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients, Parents and Caregivers (English) or Fact Sheet for Patients, Parents and Caregivers (Spanish).

BAM HCP ISI 09NOV2020

Fact Sheet for Healthcare Providers
Dear HCP Letter Correction of Drug Information: Preparation and Administration Instructions
Fact Sheet for Patients, Parents and Caregivers (English)
Fact Sheet for Patients, Parents and Caregivers (Spanish)
FDA Letter of Authorization
Terms of Use
Privacy Statement
Accessibility Statement
Sitemap
Ask Lilly

We're here to help.

Phone Call:
Lilly COVID Hotline
(1-855-545-5921)
Link Visit Lilly Medical (HCP)
Question Submit a Question

This site is intended for US healthcare providers only.

PP-BM-US-0029 12/2020 ©Lilly USA, LLC 2020. All rights reserved.

All product/company names shown herein are the trademarks of their respective owners.

Terms of Use Privacy Statement Accessibility Statement Sitemap
Lilly